Does Coffee Lower the Risk of Endometrial Cancer?


Drinking coffee multiple times a day may decrease the risk of endometrial cancer in women, according to a new study.

Women who drank three cups of coffee per day had a lower risk of endometrial cancer. Photo © topseller/

Drinking coffee multiple times a day may decrease the risk of endometrial cancer in women, according to a new study. Using dietary questionnaire results from three prospective studies on 84 different foods, the authors found that coffee intake was inversely associated with endometrial cancer risk.

In one of the studies, women who drank three cups of coffee per day-about 750 grams-had a 19% lower risk of endometrial cancer compared with women who drank less than one cup of coffee per day. Data from a different study cohort found that those who drank four cups of coffee per day-about 1,000 grams-had an 18% lower risk of endometrial cancer compared with those who did not drink coffee.

The results were published in Cancer Epidemiology, Biomarkers & Prevention.

Melissa A. Merritt, PhD, a statistician at the School of Public Health at Imperial College London in the United Kingdom, and colleagues assessed whether 84 nutrients and foods could be linked to endometrial cancer risk, using dietary questionnaires completed by 301,107 women who were between the ages of 25 and 70 at enrollment in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Of these women, 1,303 developed endometrial cancer.

From the EPIC study data, 10 foods and nutrients were found to have some association with a risk of endometrial cancer. An increased risk was associated with butter, yogurt, potatoes, and carbohydrates, while a decreased risk was associated with cheese, coffee, cream desserts, total fat, monounsaturated fat, and phosphorus.

The links between these foods and endometrial cancer risk were then further validated using a cohort of women who were part of the Nurses’ Health Study (NHS) and NHS II, from the Brigham and Women’s Hospital and Harvard School of Public Health, respectively. A total of 1,531 cases of endometrial cancer were reported from this cohort.

Only the links with butter and coffee were validated in the NHS cohort. Coffee has previously been linked to a decreased risk of endometrial cancer in both an NHS study and two prior meta-analyses.

It is not clear which components of coffee may be beneficial. One hypothesis is that coffee may be related to decreased C-peptide levels, a marker of reduced insulin secretion, which may lower exposure to estrogen and therefore obesity, said the authors in their discussion. Other studies have shown that increased intake of both caffeine and caffeine-containing coffee results in increased adiponectin levels, which is associated with lower insulin sensitivity and a decrease in estrogen levels. But, non-caffeine coffee components have also been implicated in cancer risk reduction.

“Coffee intake is worth investigating further to see if coffee can be used for the prevention of endometrial cancer. However, before clinical recommendations can be made, further studies are needed to evaluate this question in other studies and to try to isolate the components of coffee that may be responsible for any influence on endometrial cancer,” said Merritt in a statement.

Related Videos
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Dostarlimab plus chemotherapy produces notable benefits among patients with advanced, mismatch repair deficient endometrial cancer in the phase 3 RUBY trial.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
In addition to potentially moving mirvetuximab into earlier lines of treatment for those with platinum-sensitive ovarian cancer, Ritu Salani, MD, also discusses combining the agent with carboplatin to decrease toxicities and improve quality of life.
Ritu Salani, MD, details the health-related quality of life benefits associated with dostarlimab in the treatment of advanced endometrial cancer, which includes improvements in back and pelvic pain.
Ritu Salani, MD, describes the concordance between blinded independent central review and provider-assessed outcomes with dostarlimab among patients with advanced recurrent endometrial cancer in the phase 3 RUBY trial.
Related Content